James Larkin
詹姆斯·拉金
PhD, FRCP
Consultant Medical Oncologist; Professor of Renal and Skin Cancer顾问医学肿瘤科医师；肾癌与皮肤癌教授
👥Biography 个人简介
James Larkin, PhD, FRCP is a leading oncologist at The Royal Marsden Hospital specializing in both renal cell carcinoma and melanoma. He was a key investigator in CheckMate 214, establishing nivolumab plus ipilimumab in first-line RCC, and has led European initiatives in IO combination safety profiling and non-clear cell RCC treatment. His dual expertise in RCC and melanoma makes him a uniquely influential voice in immuno-oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CheckMate 214 European Leadership
Served as a principal investigator in CheckMate 214, the phase III trial establishing nivolumab plus ipilimumab superior to sunitinib in intermediate- and poor-risk first-line RCC, representing a paradigm-changing shift toward dual checkpoint blockade.
Immunotherapy-Related Adverse Events Management
Co-authored landmark analyses of immune-related adverse events (irAEs) from dual checkpoint blockade in RCC and melanoma trials, contributing essential safety data and management algorithms adopted in international clinical guidelines.
VEGFR TKI Sequencing in RCC
Led clinical investigations into optimal sequencing of VEGFR-targeted therapies including sunitinib, pazopanib, axitinib, and cabozantinib, informing European Medicines Agency-endorsed treatment algorithms for metastatic RCC.
Non-Clear Cell RCC Clinical Research
Championed dedicated trials for non-clear cell RCC at The Royal Marsden and through the UK NCRI consortium, investigating mTOR inhibitors, MET-targeted agents, and immunotherapy in papillary and other non-ccRCC histologies.
Representative Works 代表性著作
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
New England Journal of Medicine (2019)
CheckMate 067 five-year update demonstrating durable long-term survival with nivolumab plus ipilimumab in advanced melanoma, with landmark survival analyses informing combination IO strategies in RCC.
Overall Survival in Patients with Advanced Renal Cell Carcinoma: Nivolumab plus Ipilimumab versus Sunitinib (CheckMate 214 7-Year Update)
Journal of Clinical Oncology (2023)
Long-term follow-up of CheckMate 214 confirming sustained OS benefit of nivolumab plus ipilimumab in intermediate- and poor-risk metastatic RCC at 7-year median follow-up.
Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines
Annals of Oncology (2022)
ESMO guidelines co-authored by Larkin providing evidence-based recommendations for recognizing and managing immune-related adverse events across multiple tumor types.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 詹姆斯·拉金 的研究动态
Follow James Larkin's research updates
留下邮箱，当我们发布与 James Larkin（The Royal Marsden Hospital / Institute of Cancer Research）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment